Table 2.

Changes in predialysis blood or serum measurements

ParameterOxymetholone (n=19)Placebo (n=22)Difference between Groups in the Mean Change from Baseline (95% CI)
Hemoglobin (g/dl)
 Week 249.3±1.210.1±1.3
 Change from baseline0.1±1.1−0.04±1.21.17 (−0.57 to 0.91)
Fasting plasma glucose (mg/dl)
 Week 2477.3±9.483.9±26.5
 Change from baseline0.1±8.16.5±20.9−6.37 (−16.25 to 3.51)
Serum urea nitrogen (mg/dl)
 Week 2463.0±16.759.0±15.5
 Change from baseline6.4±14.6a−3.7±14.910.03 (0.71–19.35)a
Serum creatinine (mg/dl)
 Week 2412.3±2.9b11.2±1.9
 Change from baseline1.2±2.8c−0.3±1.01.47 (0.08–2.86)c
Serum albumin (g/dl)
 Week 243.9±0.34.1±0.3
 Change from baseline0.1±0.3−0.02±0.20.09 (−0.09 to 0.27)
Serum AST (U/L)
 Week 2447.8±45.5b15.3±7.8
 Change from baseline31.7±32.5c1.5±6.530.15 (14.27–46.03)c
Serum ALT (U/L)
 Week 2470.1±71.3b15.6±7.5
 Change from baseline55.5±50.6c2.5±6.453.02 (28.44–77.56)c
Serum total bilirubin (mg/dl)
 Week 240.8±1.00.3±0.1
 Change from baseline0.5±0.7c−0.01±0.10.47 (0.13–0.81)b
Serum direct bilirubin (mg/dl)
 Week 240.51±0.77d0.10±0.06
 Change from baseline0.42±0.54a0.00±0.040.42 (0.16–0.68)a
Number of patients with
 AST more than three times the ULN0 (0.0)0 (0.0)
 ALT more than three times the ULN2 (9.5)0 (0.0)
 TB>2 mg/dl3 (14.3)0 (0.0)
  • Values were all obtained immediately before the onset of a hemodialysis treatment. Data are mean ± SD. CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal; TB, total bilirubin.

  • a Compared with placebo: P<0.05.

  • b Week 24 value compared with baseline: P<0.01.

  • c Compared with placebo: P<0.01.

  • d Week 24 value compared with baseline: P<0.05.